Loading clinical trials...

Trial to Study Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy | Clinical Trials | Clareo Health

COMPLETEDNA

Trial to Study Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy

A Single-Arm Pilot Study of the Feasibility and Efficacy of Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy

NCT07455409•The Methodist Hospital Research Institute

View on ClinicalTrials.gov

Summary

This study will determine the feasibility and efficacy of a 10-treatment electro-acupuncture (EA) program in subjects with chemotherapy-induced peripheral neuropathy (CIPN). The Investigators hypothesize that EA will be a feasible and effective therapy for CIPN.

Detailed Description

This is a single-arm pilot study assessing the feasibility and efficacy of EA in 20 subjects with CIPN. The primary objective is to determine the feasibility of a 10-treatment EA program in subjects with CIPN. Feasibility will be defined as ≥15 patients completing ≥8 EA treatments. Secondary objectives include change in neuropathic pain and quality of life before and after EA treatment. An exploratory correlative analysis of mechanistic biomarkers will also be performed.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female aged ≥18 years
•Received curative-intent chemotherapy (i.e., paclitaxel, docetaxel, nab-paclitaxel, carboplatin, oxaliplatin, vinorelbine, ixabepilone, or vincristine) ≥3 months prior to the start of EA treatment
•Persistent Grade ≥2 peripheral neuropathy in the fingers or toes according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
•Eastern Cooperative Oncology Group performance status of ≤2 (see Section 13.3)
•Willing and able to provide written informed consent for the study.

Exclusion Criteria

•Documented medical history of neuropathy resulting from nerve compression (e.g., carpal tunnel syndrome, radiculopathy, or spinal stenosis)
•Severe coagulopathy or bleeding disorder, per the treating physician's discretion
•Presence of cellulitis or other skin infection or condition that would preclude placement of acupuncture needles into the hands or feet
•Diabetes unless Hgb A1c \<7.5%
•Unstable cardiac disease
•Pacemaker
•Metal plates
•Known psychiatric disorder that would interfere with cooperation with the requirements of the study
•Pregnant

Locations (1)

Houston Methodist Neal Cancer Center

Houston, Texas, United States

Key Dates

Start Date

August 29, 2019

Primary Completion Date

August 18, 2023

Completion Date

August 18, 2023

Last Updated

March 6, 2026

Enrollment

ACTUAL participants

Conditions

Chemotherapy-induced Peripheral Neuropathy

Interventions

Electro-acupuncture

DEVICE

Use of PEA and Scutellaria in Synergy With Therapeutic Exercise in Chemotherapy-induced Peripheral Neuropathy (CIPN): a Clinical Trial

NCT07352514

Chemotherapy-induced Peripheral Neuropathy (CIPN)Neuropathic Pain

View study

RECRUITINGNA

Cryocompression for CIPN

NCT07064798

Chemotherapy-induced Peripheral NeuropathyTaxane-Induced Peripheral Neuropathy+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trial to Study Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria

Exclusion Criteria

Use of PEA and Scutellaria in Synergy With Therapeutic Exercise in Chemotherapy-induced Peripheral Neuropathy (CIPN): a Clinical Trial

Cryocompression for CIPN

Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

International CIPN Assessment and Validation Study

Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy